LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 12.28 | 770.25 | 1190 | 1358 | 0.8762 | 0.7017 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 12.28 | 770.25 | 1420 | 1358 | 1.0456 | 1.1119 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 14.50 | 770.25 | 1302 | 1497 | 0.8696 | 0.7288 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 14.50 | 770.25 | 1608 | 1497 | 1.0740 | 1.1545 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 16.73 | 770.25 | 1444 | 1664 | 0.8675 | 0.7600 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 16.73 | 770.25 | 1783 | 1664 | 1.0712 | 1.1276 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 18.95 | 770.25 | 1590 | 1832 | 0.8677 | 0.7854 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 18.95 | 770.25 | 1946 | 1832 | 1.0619 | 1.0985 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 21.17 | 770.25 | 1748 | 2008 | 0.8704 | 0.8089 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 21.17 | 770.25 | 2113 | 2008 | 1.0521 | 1.0748 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 23.39 | 770.25 | 1946 | 2244 | 0.8670 | 0.8233 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 23.39 | 770.25 | 2356 | 2244 | 1.0497 | 1.0638 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 25.62 | 770.25 | 2192 | 2514 | 0.8716 | 0.8453 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 25.62 | 770.25 | 2609 | 2514 | 1.0374 | 1.0435 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 27.84 | 770.25 | 2431 | 2833 | 0.8578 | 0.8433 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 27.84 | 770.25 | 2890 | 2833 | 1.0198 | 1.0210 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 30.06 | 770.25 | 2693 | 3106 | 0.8670 | 0.8630 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 30.06 | 770.25 | 3147 | 3106 | 1.0132 | 1.0130 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 32.28 | 770.25 | 2892 | 3392 | 0.8524 | 0.8561 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 32.28 | 770.25 | 3488 | 3392 | 1.0280 | 1.0260 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 34.50 | 770.25 | 3182 | 3712 | 0.8572 | 0.8687 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 34.50 | 770.25 | 3746 | 3712 | 1.0092 | 1.0081 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 36.73 | 770.25 | 3507 | 4086 | 0.8583 | 0.8770 | MN20160304_L02 | E16 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 36.73 | 770.25 | 4134 | 4086 | 1.0117 | 1.0097 | MN20160304_L02 | E21 |
| MCF 10A-H2B-mCherry | Trametinib | 0.00033333 | 38.95 | 770.25 | 3930 | 4543 | 0.8649 | 0.8898 | MN20160304_L02 | E16 |